VYNE

Latest SEC Filings & News for VYNE

4 most recent filings and news items mentioning VYNE. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day
curl "https://api.brieftape.com/v1/tickers/VYNE/news?limit=20"

Pull VYNE filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day

Vyne Therapeutics approves 1-for-50 reverse stock split for Nasdaq listing

Vyne Therapeutics Inc. announced a 1-for-50 reverse stock split and a special cash dividend of $17.3 million ahead of its pending merger with Yarrow Bioscience, facilitating the combined company's transition to the ticker YARW.

View filing at SEC.gov →

VYNE Therapeutics files presentation regarding proposed reverse merger.

VYNE Therapeutics filed Exhibit 99.1 detailing a proposed reverse merger with Yarrow Bioscience and concurrent financing. This corporate restructuring could provide VYNE's preclinical programs with necessary capital and strategic oversight.

View filing at SEC.gov →

Vyne declares special $16.5M dividend in connection with merger

VYNE Therapeutics Inc. announced a special cash dividend of approximately $16.5 million, or $0.38 per share, linked to its pending acquisition by Yarrow Bioscience. The distribution is contingent on the successful completion of the transaction.

View filing at SEC.gov →

VYNE Therapeutics presents Yarrow Bioscience overview ahead of proposed reverse merger transaction

VYNE Therapeutics filed an exhibit containing a Yarrow Bioscience company overview presentation dated May 2026, indicating preparation for a proposed reverse merger transaction with concurrent financing. The filing suggests potential corporate restructuring activity that could ma

View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.